Preoperative prediction of the need for postoperative adjuvant therapy in stage IB cervical cancer using tumor size measured on magnetic resonance imaging and serum squamous cell carcinoma antigen levels
Michihide Maeda, Miho Kitai, Masashi Akada, Yusaku Shimizu, Eri Yamabe, Reisa Kakubari, Shinya Matsuzaki, Tsuyoshi Hisa, Shinsuke Koyama, Seiji Mabuchi · 2026
Read Preoperative prediction of the need for postoperative adjuvant therapy in stage IB cervical cancer using tumor size measured on magnetic resonance imaging and serum squamous cell carcinoma antigen levels by Michihide Maeda, Miho Kitai, Masashi Akada, Yusaku Shimizu, Eri Yamabe, Reisa Kakubari, Shinya Matsuzaki, Tsuyoshi Hisa, Shinsuke Koyama, Seiji Mabuchi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13427441.txt.
Description
Michihide Maeda and coauthors tested preoperative predictors of extra therapy after surgery for stage IB cervical cancer in a 2026 retrospective study of 191 patients. Radical hysterectomy is standard at this stage, yet many patients then need adjuvant treatment, exposing them to dual-modality burdens. Candidate predictors were tumor size on MRI scans and blood levels of squamous cell carcinoma antigen measured before surgery.
Receiver operating analysis set cutoff values for each marker, with a focused look at stage IB1 to IB2 cases. Knowing likely adjuvant need before surgery helps counseling about combined treatment and fertility or recovery trade-offs.
Catalog record
| CREATOR | Michihide Maeda, Miho Kitai, Masashi Akada, Yusaku Shimizu, Eri Yamabe, Reisa Kakubari, Shinya Matsuzaki, Tsuyoshi Hisa, Shinsuke Koyama, Seiji Mabuchi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39243 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |